The TKI imatinib, the first agent targeting the TK activity of BCR-ABL1 protein, has become the first-line therapy for all patients with Ph-positive CML; it is also an indispensable therapy for Ph-positive ALL. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.